<DOC>
	<DOCNO>NCT01954394</DOCNO>
	<brief_summary>Primary Objective : To assess long-term safety alirocumab add lipid-lowering therapy patient heterozygous familial hypercholesterolemia ( heFH ) . Secondary Objectives : To evaluate long-term efficacy alirocumab lipid parameter . To evaluate long-term immunogenicity alirocumab .</brief_summary>
	<brief_title>Open Label Study Long Term Safety Evaluation Alirocumab</brief_title>
	<detailed_description>The maximum study duration 176 week per patient .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Patients heFH complete one four parent study ( EFC12492 , R727CL1112 , EFC12732 LTS11717 ) . Exclusion criterion : Significant protocol deviation parent study ; Any permanent treatment discontinuation parent study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>